AstraZeneca: China approves Fasenra for severe asthma

(CercleFinance.com) - AstraZeneca announced on Tuesday that China's drug agency has approved its monoclonal antibody Fasenra for the treatment of severe eosinophilic asthma.


The company explains that the approval by China's National Medical Products Administration (NMPA) is for the maintenance treatment of the disease in individuals aged at least 12 years.

Its approval is based on the results of Phase III clinical trials conducted in China, South Korea and the Philippines, in which Fasenra achieved a 74% reduction in the annual rate of asthma exacerbations, in combination with standard treatment.

AstraZeneca states that severe eosinophilic asthma affects around three million people in China.

Fasenra, a monoclonal antibody that recruits natural killer cells, results in almost total depletion of eosinophils, cells present in around 50% of asthma patients.

The drug, which takes the form of a pre-filled syringe to be injected subcutaneously once every two months, is now approved in 80 countries, including the US, the EU and Japan.


Copyright (c) 2024 CercleFinance.com. All rights reserved.